Edition:
United States

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

33.21USD
21 Feb 2018
Change (% chg)

$1.37 (+4.30%)
Prev Close
$31.84
Open
$31.84
Day's High
$34.35
Day's Low
$31.81
Volume
64,203
Avg. Vol
111,992
52-wk High
$41.80
52-wk Low
$14.00

Select another date:

Mon, Feb 12 2018

BRIEF-Wellington Management Group Llp Reports 10.85 pct Passive Stake In Audentes Therapeutics As Of Jan 31, 2018

* WELLINGTON MANAGEMENT GROUP LLP REPORTS 10.85 PERCENT PASSIVE STAKE IN AUDENTES THERAPEUTICS INC AS OF JANUARY 31, 2018 - SEC FILING‍​ Source text - (http://bit.ly/2nZykxi) Further company coverage:

BRIEF-Audentes Therapeutics Says Public Offering Of 5.75 Mln Shares Priced At $35/Share

* AUDENTES THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Audentes Therapeutics To Offer $150 Million Of Common Stock In Public Offering​

* AUDENTES THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro

* AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

BRIEF-Audentes Therapeutics Q3 ‍loss per share $ 0.88​

* Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Audentes Therapeutics to release Q3 financial results Nov. 14

* Audentes Therapeutics to release third quarter 2017 financial results and provide corporate update on Tuesday, November 14, 2017 Source text for Eikon: Further company coverage:

BRIEF-Audentes Therapeutics gets fast track designation for its muscle disorder drug

* Audentes Therapeutics announces rare pediatric disease and fast track designations for AT132 for the treatment of x-linked myotubular myopathy

BRIEF-Audentes Therapeutics commences dosing of first patient in phase 1/2 trial of AT132 for the treatment of x-linked myotubular myopathy

* Audentes Therapeutics announces dosing of first patient in ASPIRO, a phase 1/2 clinical trial of AT132 for the treatment of X-linked myotubular myopathy

Select another date: